Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Zai Lab (NASDAQ:ZLAB) on Sunday, setting a price target of $225, which is approximately 50.00% above the present share price of $150.
Yee expects Zai Lab to post earnings per share (EPS) of -$2.64 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Zai Lab, with an average price target of $214.67.
The analysts price targets range from a high of $225 to a low of $202.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $20.1 million and a net profit of -$227.09 million. The company's market cap is $11.31 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.8% and a 49.52% success rate.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.